Company: LHI
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006939
Chunk: 2

Company: Living Homeopathy International Ltd.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 2
---
,” and when referring to the consolidated company including the Company’s subsidiaries, “we”, “us”), par value $0.0001 per share (each, a “Class A Ordinary Share”, collectively, “Class A Ordinary Shares”). The estimated initial public offering price for the Class A Ordinary Shares in the offering is expected to be between $[●] and $[●] per Class A Ordinary Share.

Living Homeopathy will reserve the symbol “LHI” for the purpose of listing its Class A Ordinary Shares on the Nasdaq Capital Market, or Nasdaq. This offering is contingent upon the final approval from Nasdaq for the listing of Living Homeopathy’s Class A Ordinary Shares on the Nasdaq Capital Market. Living Homeopathy will not proceed to consummate this offering if Nasdaq denies its listing application. However, there can be no guarantee or assurance that the offering will be closed and Living Homeopathy’s Class A Ordinary Shares will be approved for trading on the Nasdaq Capital Market.

Investing in our Class A Ordinary Shares involves a high degree of risk, including the risk of losing your entire investment. See “Risk Factors” beginning on page 16 of this prospectus to read about factors you should consider before buying our Class A Ordinary Shares.

We are an “emerging growth company” as defined under the federal securities laws and will be subject to reduced public company reporting requirements. See “ Risk Factors” and “ Prospectus Summary — Implications of Being an “Emerging Growth Company” on pages 11 and 12, respectively.

Immediately prior to the
completion of this offering, our issued and outstanding share capital consists of 9,000,000 Class A Ordinary Shares and 1,000,000 Class
B ordinary shares, par value $0.0001 per share (each, a “Class B Ordinary Share,” collectively, “Class B Ordinary Shares”),
and immediately after the completion of this offering, our outstanding share capital will remain consisting of Class A Ordinary Shares
and Class B Ordinary Shares. As of the date of this prospectus, Mr. Ka Lun To, our Chairman and Chief Executive Officer, is beneficially
interested in 4,680,000 Class A Ordinary Shares and 520,000 Class B Ordinary Shares, representing approximately 52% of our total voting
power and immediately after the completion of this offering, Mr. To, will continue to be beneficially interested in 4,680,000 Class A
Ordinary Shares and 520,000 Class B Ordinary Shares, representing approximately